Biovica International B — Investor Relations & Filings

Biovica International is a biotechnology company that develops and commercializes blood-based biomarker assays to improve cancer therapy monitoring. The company's primary product is the DiviTum® TKa Test, a blood test that measures cell proliferation by analyzing thymidine kinase activity. This assay is designed to monitor disease progression and evaluate treatment efficacy for patients with solid tumors, with a particular focus on metastatic breast cancer. The test provides oncologists with critical data to predict patient outcomes and make more informed therapeutic decisions, especially for those on modern treatments like CDK4/6 inhibitors. The technology is utilized in both clinical settings and pharmaceutical research to enhance cancer care.